The CD6/ALCAM pathway promotes lupus nephritis via T cell–mediated responses
Authors:
- Samantha A. ChalmersSCSamantha A. Chalmers
- Sayra J. GarciaSGSayra J. Garcia
- Evan DerEDEvan Der
- Leal HerlitzLHLeal Herlitz
- Jeanette AmpudiaJAJeanette Ampudia
- Dalena ChuDCDalena Chu
- Nicole JordanNJNicole Jordan
- Ting ZhangTZTing Zhang
- Ioannis ParodisIPIoannis Parodis
- Iva GunnarssonIGIva Gunnarsson
- Huihua DingHDHuihua Ding
Top Cited Papers
Open Access
- 4 January 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (1)
Abstract
T cells are central to the pathogenesis of lupus nephritis (LN), a common complication of systemic lupus erythematosus (SLE). CD6 and its ligand, activated leukocyte cell adhesion molecule (ALCAM), are involved in T cell activation and trafficking. Previously, we showed that soluble ALCAM is increased in urine (uALCAM) of patients with LN, suggesting that this pathway contributes to disease. To investigate, uALCAM was examined in 1038 patients with SLE and LN from 5 ethnically diverse cohorts; CD6 and ALCAM expression was assessed in LN kidney cells; and disease contribution was tested via antibody blockade of CD6 in murine models of SLE and acute glomerulonephritis. Extended cohort analysis offered resounding validation of uALCAM as a biomarker that distinguishes active renal involvement in SLE, irrespective of ethnicity. ALCAM was expressed by renal structural cells whereas CD6 expression was exclusive to T cells, with elevated numbers of CD6+ and ALCAM+ cells in patients with LN. CD6 blockade in models of spontaneous lupus and immune-complex glomerulonephritis revealed significant decreases in immune cells, inflammatory markers, and disease measures. Our data demonstrate the contribution of the CD6/ALCAM pathway to LN and SLE, supporting its use as a disease biomarker and therapeutic target.Keywords
Funding Information
- National Institutes of Health (UH2-AR067676,UH2-AR067677,UH2-AR067679,UH2-AR067681,UH2-AR067685,UH2-AR067688,UH2-AR067689,UH2-AR067690,UH2-AR067691,UH2-AR067694,UM2-AR067678,AR074096,AR069572,AR067679,DK079328)
- Swedish Rheumatism Association (R-932236)
- King Gustaf V’s 80-year Foundation (FAI-2019-0635)
- Professor Nanna Svartz foundation (2019-00290)
- Ulla and Roland Gustafsson Foundation (2019-12)
This publication has 65 references indexed in Scilit:
- IL-17-producing double-negative T cells are expanded in the peripheral blood, infiltrate the salivary gland and are partially resistant to corticosteroid therapy in patients with Sjögren’s syndromeReumatismo, 2013
- Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosusCurrent Opinion in Rheumatology, 2011
- Th Subset Balance in Lupus NephritisBioMed Research International, 2011
- CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interactionClinical and Experimental Immunology, 2010
- IL-9 induces differentiation of T H 17 cells and enhances function of FoxP3 + natural regulatory T cellsProceedings of the National Academy of Sciences, 2009
- CXCR4/CXCL12 Hyperexpression Plays a Pivotal Role in the Pathogenesis of LupusThe Journal of Immunology, 2009
- Yaa autoimmune phenotypes are conferred by overexpression of TLR7European Journal of Immunology, 2008
- The ALCAM Shedding by the Metalloprotease ADAM17/TACE Is Involved in Motility of Ovarian Carcinoma CellsMolecular Cancer Research, 2007
- CD6 Regulates T-Cell Responses through Activation-Dependent Recruitment of the Positive Regulator SLP-76Molecular and Cellular Biology, 2006
- Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cellsBlood, 2006